Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled Olcegepant (BIBN 4096 BS) in Healthy Volunteers
NCT02199860Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2003
- Primary completion
- Feb 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of olcegepant in migraine (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with adverse events up to 25 days, Assessment of tolerability on a 4-point scale and 3 more. Started May 2003; status: completed.
02
Drugs
olcegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02199860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199860.